-
Sep 9, 2024 | 
onclive.com | Komal Jhaveri
Commentary Video September 9, 2024 Supplements and Featured Publications Exacting the Role of Novel Endocrine Therapies in ER+ Metastatic Breast Cancer Author(s): Komal Jhaveri, MD, FACP, section head, Endocrine Therapy Research Program, clinical director, Early Drug Development Service, Patricia and James Cayne Chair for Junior Faculty, Memorial Sloan Kettering Cancer Center, discusses the current state of the frontline treatment paradigm, as well as ongoing developments, for patients with...
-
Aug 22, 2024 | 
onclive.com | Komal Jhaveri
CommentaryPodcastAugust 22, 2024Author(s):Fact checked by:Dr Jhaveri discusses the INAVO120 trial of inavolisib plus palbociclib and fulvestrant in PIK3CA-mutant, HR-positive metastatic breast cancer. Welcome to OncLive On Air®! I’m your host today, Ashling Wahner. OncLive On Air is a podcast from OncLive®, which provides oncology professionals with the resources and information they need to provide the best patient care.
-
Jul 17, 2024 | 
onclive.com | Komal Jhaveri
CommentaryVideoJuly 17, 2024Author(s):Komal Jhaveri, MD, FACP, discusses the evolution of antibody-drug conjugates for patients with HER2-positive, HER2-low or HER2-ultralow metastatic breast cancer.
-
Jul 1, 2024 | 
onclive.com | Komal Jhaveri
Komal Jhaveri, MD, FACP, section head, Endocrine Therapy Research Program, clinical director, Early Drug Development Service, Patricia and James Cayne Chair for Junior Faculty, Memorial Sloan Kettering Cancer Center, discusses the clinical implications of the phase 3 DESTINY-Breast06 trial (NCT04494425) for patients with hormone receptor–positive, HER2-low or -ultralow metastatic breast cancer.
-
Jun 7, 2024 | 
onclive.com | Komal Jhaveri
CommentaryVideoJune 7, 2024Supplements and Featured PublicationsClinical Updates in PIK3CA+ Metastatic Breast CancerAuthor(s):Komal Jhaveri, MD, FACP, discusses the implications of investigating treatment with RLY-2608 in patients with PIK3CA-mutant advanced ER+ breast cancer.
-
Feb 2, 2024 | 
obroncology.com | Komal Jhaveri |Robert A. Figlin
CDK4/6 inhibitors “have really been a game changer” in metastatic breast cancer, according to Komal Jhaveri, MD, clinical director for early drug development and section head for endocrine therapy research at Memorial Sloan Kettering in New York City. However, optimal treatment strategies have been complicated by a lack of head-to-head trials. Dr. Jhaveri speaks with Robert A.
-
Jan 29, 2024 | 
onclive.com | Komal Jhaveri
Inavolisib or Placebo in Combination With Palbociclib and Fulvestrant in Patients With PIK3CA Mutated, Hormone Receptor Positive, HER2 Negative Locally Advanced or Metastatic Breast Cancer: Phase III INAVO120 Primary AnalysisKomal L. Jhaveri, MD, FACP, presents key data on the addition of inavolisib to palbociclib and fulvestrant vs palbociclib and fulvestrant alone in select patients with PIK3CA-mutated, hormone receptor–positive, HER2-negative, locally advanced, or metastatic breast cancer.
-
Dec 21, 2023 | 
onclive.com | Komal Jhaveri
Komal Jhaveri, MD, FACP, section head, Endocrine Therapy Research Program, clinical director, Early Drug Development Service, Patricia and James Cayne Chair for Junior Faculty, Memorial Sloan Kettering Cancer Center, discusses the rationale for investigating lasofoxifene plus abemaciclib (Verzenio) in patients with ESR1-mutated estrogen receptor (ER)–positive, HER2-negative metastatic breast cancer.
-
Dec 21, 2023 | 
onclive.com | Komal Jhaveri
Laura A. Huppert, MD, breast medical oncologist, assistant professor, University of California, San Francisco School of Medicine, discusses the impact of sequential treatment with fam-trastuzumab deruxtecan-nxki (T-DXd; Enhertu) and sacituzumab govitecan-hziy (Trodelvy) on outcomes in patients with HER2-low metastatic breast cancer, according to findings from a retrospective analysis.
-
Nov 15, 2023 | 
onclive.com | Komal Jhaveri
Komal Jhaveri, MD, FACP, section head, Endocrine Therapy Research Program, clinical director, Early Drug Development Service, Patricia and James Cayne Chair for Junior Faculty, Memorial Sloan Kettering Cancer Center, discusses unmet needs for patients with breast cancer, as well as ways to address these needs through discussion and collaboration. Jhaveri was co-chair of the 2023 Bridging the Gaps in Breast Cancer meeting.
